Fenethylline Stats & Data

Reasoning for key harm-reduction updates: 1) Modern “Captagon” tablets are almost universally amphetamine-based counterfeits, not fenethylline. Multiple EMCDDA/EUDA reports show EU-seized tablets typically contain amphetamine (often with caffeine) and no fenethylline; some analyses estimate ≈32 mg amphetamine sulfate per tablet. This means dose/effect expectations for genuine fenethylline do not apply to street tablets; accurate identification requires instrumental analysis (e.g., GC/MS or LC-MS). 2) Fenethylline is a codrug cleaved to amphetamine and theophylline in vivo; the methylxanthine fraction contributes adenosine antagonism and PDE inhibition, raising heart rate and excitability and—at higher exposures—seizure risk. Thus, avoiding extra caffeine and being alert to theophylline-like toxicity (nausea, tremor, tachyarrhythmia) is prudent. 3) Stimulants combined with MAOIs can precipitate hypertensive crisis; standard references list amphetamine as contraindicated within 14 days of MAOI therapy. Treat fenethylline with the same caution because its active stimulant metabolite is amphetamine. 4) Mixing with serotonergic antidepressants and CYP2D6 inhibitors increases serotonin-syndrome risk for amphetamine; monitor closely or avoid. 5) Theophylline is metabolized mainly by CYP1A2; inhibitors can raise levels and toxicity. This underpins caution with drugs that inhibit CYP1A2 and with heavy caffeine co-use. 6) Urinary pH strongly modulates amphetamine elimination; alkalinization prolongs effects/toxicity, while acidification increases clearance. Users should avoid deliberate alkalinization when concerned about over-stimulation. 7) Environment/heat: stimulants elevate body temperature; hot indoor/outdoor settings increase the risk of hyperthermia and organ damage—plan cooling breaks and hydration with electrolytes. 8) General stimulant harm reduction advises avoiding polystimulant stacks and using test services where possible; EUDA notes that reagents are insufficient to verify fenethylline—instrumental drug checking is needed. 9) Cardiovascular screening: amphetamine-class agents are contraindicated in significant cardiovascular disease/hyperthyroidism/glaucoma; treat fenethylline similarly due to its active amphetamine metabolite and theophylline side-effects. 10) Legal status: fenethylline is internationally controlled (e.g., US Schedule I; UN Psychotropics Schedule II); possession/supply penalties may be severe.